FibroBiologics, Inc.
Close on Oct 19, 2026
- Market cap
- $5.92M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
FibroBiologics has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements FibroBiologics filed with the SEC
FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
FibroBiologics Compliant with All Nasdaq Listing Requirements
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
FibroBiologics Announces Pricing of $3 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Announces Closing of $3 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Announces $1.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
FibroBiologics Announces Pricing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Closes Third $5 Million Tranche of $25 Financing
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Appoints Jason D. Davis, CPA, as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Closes Second $5 Million Tranche of $25 Million Financing
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
December 23, 2024/Globe Newswire/ – FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
have a pipeline of product candidates at various stages of development, including the following:
Other events · EX-99.1 to Form 8-K
FibroBiologics to Present Preclinical and Clinical
Other events · EX-99.1 to Form 8-K
Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
Other events · EX-99.1 to Form 8-K
FibroBiologics Announces Three United States Patents
Other events · EX-99.1 to Form 8-K
Announces Three Japanese Patents on Fibroblast Technology
Other events · EX-99.1 to Form 8-K
Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG
Other events · EX-99.1 to Form 8-K